Live
FierceBiotechHow a new tool for large-scale gene editing could power novel genetic medicinesFierceBiotechStryker hit by international cyberattack linked to pro-Iran groupFierceBiotechEvotec reveals sweeping 800-person layoffs, more site closures as restructuring rolls onFierceBiotechAgilent to acquire Biocare in $950M 'complementary combination'Endpoints NewsEvotec plans up to 800 job cuts, four site closuresEndpoints NewsFDA merges adverse event trackers into one databaseBioPharma DiveBiogen builds case for Spinraza successor with fresh dataCellMicrobiome-produced nicotinic acid controls colon regional identity and injury susceptibilityCellPapuan admixture predated the settlement of PalauFierceBiotechCNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targetsFierceBiotechBD taps Sinteco for European pharmacy robotics partnershipFierceBiotechDespite delays, NIH grants generated a 250% return on $36.6B investment in 2025: report
FierceBiotech Mar 11, 2026

How a new tool for large-scale gene editing could power novel genetic medicines

How a new tool for large-scale gene editing could power novel genetic medicines

Original
Body unavailable. Use the original source.

Directory

59 All